• Etanercept (enbrel®) for the treatment of moderate to severe plaque type psoriasis.

    Piérard-Franchimont C. , Piérard G.E.
    Rev Med Liege 2006, 61(3),201-205

    Abstract : Etanercept (Enbrel®) is a soluble tumour necrosis factor (TNF) receptor drug. By this mechanism, it inhibits the effects of TNF-α involved in the pathogenesis of psoriasis. Enbrel® is approved for the treatment of moderate to severe chronic plaque psoriasis, and also for psoriatic arthritis.

    Resources available :